Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Siemens Healthcare Diagnostics, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Siemens Healthcare Diagnostics, Inc.

Regulatory records
26
Linked recall entries
41
Headquarters
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 26 FDA records to the applicant name Siemens Healthcare Diagnostics, Inc.. The collection includes 6 510(k) clearances. It includes 4 original PMA approvals. 7 entries are PMA supplements. 9 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 15, 1995 to Nov 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MTF appears in 9 of the 26 linked filings. The collection spans 10 FDA product codes and 8 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P930027, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 4 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 511 Benedict Ave., Tarrytown, NY, 10591, US. Recorded on K260674, decision dated Nov 6, 2026.

Changes described in PMA records

P010007/S028: IMMULITE Systems AFP

The FDA record for P010007/S028, under the title IMMULITE Systems AFP with decision OK30 dated 2026-09-22, is a 30-Day Notice whose supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. The stated change is to move manufacturing of a critical component within the same facility. The notice does not describe the component, its function, the affected manufacturing steps, or any validation or comparability data supporting the move.

The identifier P010007 ties this supplement to the original PMA for an alpha-fetoprotein kit for neural tube defects, product code LOK, with Siemens Healthcare Diagnostics, Inc. as applicant. It is a supplement notice concerning a manufacturing location change, not a new approval of the whole system, and the reported purpose does not by itself establish safety or clinical effectiveness. The record is silent on whether analytical performance or previously cleared indications are affected.

FDA approval-order wording

to move manufacturing of a critical component within the same facility

Sep 22, 2026 · 30-Day Notice

P930027/S041: IMMULITE Systems PSA

The FDA record for P930027/S041 lists a 30-day notice for IMMULITE Systems PSA, with the stated purpose of moving manufacturing of a critical component within the same facility. The notice reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. The record does not name the component, the facility, or the manufacturing steps involved, so the scope of the change cannot be described beyond the field labels.

The identifier ties this supplement to the original PMA P930027, which covers total prostate specific antigen testing for detection of prostate cancer under product code MTF in Immunology, submitted by Siemens Healthcare Diagnostics, Inc. A supplement is not a new approval of the whole system, and a manufacturing notice is not an original PMA. The reported purpose of the move does not by itself establish safety or clinical effectiveness.

FDA approval-order wording

to move manufacturing of a critical component within the same facility

Sep 22, 2026 · 30-Day Notice

P240021/S001: Atellica IM Total PSA II (tPSAII)

FDA’s recorded scope: Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica CI Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.

Aug 26, 2026 · Normal 180 Day Track

P010007/S027: IMMULITE Systems AFP

FDA’s recorded scope: Approval of the change to the bead drying process used in the manufacture of bead components for the IMMULITE 2000 AFP, Free PSA, and PSA assays.

Aug 20, 2026 · 30-Day Notice

P930027/S040: IMMULITE Systems PSA

FDA’s recorded scope: Approval of the change to the bead drying process used in the manufacture of bead components for the IMMULITE 2000 AFP, Free PSA, and PSA assays.

Aug 20, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 41 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 39 Class II, 2 Class III records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Search the firm’s recall records
Source information

Source updated Nov 11, 2026. Retrieved Nov 21, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.510(k) clearanceNov 6, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 26, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
Siemens Healthcare Diagnostics, Inc.510(k) clearanceAug 10, 2026FDA
IMMULITE 2000 PSAP930027/S039
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
IMMULITE 2000 AFPP010007/S026
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.510(k) clearanceJul 24, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementMay 11, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA approvalMay 11, 2026FDA
IMMULITE 2000 AFPP010007/S025
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA
IMMULITE 2000 PSAP930027/S038
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA
Siemens Healthcare Diagnostics, Inc.510(k) clearanceFeb 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.510(k) clearanceFeb 6, 2026FDA
Siemens Healthcare Diagnostics, Inc.510(k) clearanceJan 5, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA approvalDec 3, 2025FDA
IMMULITE 2000 AFPP010007/S024
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 30, 2025FDA
IMMULITE 2000 PSAP930027/S037
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 30, 2025FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 17, 2025FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 17, 2025FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 17, 2025FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 14, 2025FDA
Siemens Healthcare Diagnostics, Inc.PMA approvalNov 9, 2001FDA
Siemens Healthcare Diagnostics, Inc.PMA approvalSep 15, 1995FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.